Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARZAN: Neoadjuvant radiotherapy followed by atezolizumab and bevacizumab in rectal cancer
2018-002463-25Phase 2Active
- Sponsor
- Netherlands Cancer Institute
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab and bevacizumab in rectal adenocarcinoma and rectal cancer, sponsored by Netherlands Cancer Institute. Primary endpoint: Clinical complete and near-complete response rate. Started Aug 2018; status: active.
02
Drugs
atezolizumabbevacizumab
03
Conditions
rectal adenocarcinomarectal cancer
Beyond the preview
Go deeper on 2018-002463-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002463-25.